PERSPECTA

News from every angle

← Back to headlines

Analyse: Her er problemet, der forfølger Novo Nordisk – og igen koster investorerne dyrt

Så er den gal igen. Novo Nordisks aktiekurs styrtdykker med omkring 14 procent mandag. Det hele begyndte en sensommerdag i 2022.

23 Feb, 13:09 — 23 Feb, 13:09
PostShare

Sources

Showing 1 of 2 sources
YahooMostly Factual168d ago

Novo Nordisk's next obesity drug falls short of Lilly rival, wiping billions off its market value

Read full article →

Coverage Timeline

First report: berlingske · 23 Feb, 12:33Full coverage: 2 · 35mWindow: 35m
Left-leaningCenterRight-leaning
berlingske23 Feb, 12:33First to report

Analyse: Her er problemet, der forfølger Novo Nordisk – og igen koster investorerne dyrt

Yahoo23 Feb, 13:09Latest update

Novo Nordisk's next obesity drug falls short of Lilly rival, wiping billions off its market value

Related Stories

Large Fire Breaks Out at Pallet Company in Lelystad, Netherlands

10m ago

Hungary Faces Energy Storage Deficit Amidst Energy Crisis

10m ago

Underground Utility Works Impede Tram Track Upgrades in Bucharest

11m ago

North Macedonia's Public Revenue Office Trains for E-Invoice System

13m ago